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Abstract Tenascin-C is an extracellular matrix glyco-
protein that is speciﬁcally and transiently expressed upon
tissue injury. Upon tissue damage, tenascin-C plays a
multitude of different roles that mediate both inﬂammatory
and ﬁbrotic processes to enable effective tissue repair. In
the last decade, emerging evidence has demonstrated a
vital role for tenascin-C in cardiac and arterial injury,
tumor angiogenesis and metastasis, as well as in modu-
lating stem cell behavior. Here we highlight the molecular
mechanisms by which tenascin-C mediates these effects
and discuss the implications of mis-regulated tenascin-C
expression in driving disease pathology.
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123Introduction
Tenascin-C is a large hexameric extracellular glycoprotein.
The founding member of a family of four tenascins, it is
unique in its distinct pattern of expression. Little or no
tenascin-C is detected in healthy adult tissues. It is tran-
siently re-expressed upon tissue injury, and down-regulated
after tissue repair is complete [1]. Tenascin-C is a multi-
modular protein comprising four distinct domains: an
assembly domain, a series of epidermal growth factor-like
repeats (EGF-L), a series of ﬁbronectin type III-like repeats
(FNIII), and a C-terminal ﬁbrinogen-like globe (FBG).
Each of these domains can interact with a different subset
of binding partners, including cell surface receptors and
other extracellular components (Fig. 1)[ 2]. By virtue of
this domain organization, tenascin-C is an extraordinarily
pleiotropic molecule and mediates a wide range of func-
tions during tissue injury. Here we focus on recent
discoveries, areas in which signiﬁcant advances have been
made in our understanding of the action of tenascin-C in
cardiac and arterial injury, tumor angiogenesis, and stem
cell biology.
New clinical indications: tenascin-C in cardiac
pathology
Cardiovascular diseases such as myocardial infarction
(MI), hypertension, hypertrophy, or heart failure are all
accompanied by changes in the composition of the cardiac
extracellular matrix (ECM). These dynamic alterations not
only determine the mechanical properties of the damaged
heart but also directly modulate the inﬂammatory and
reparative response (reviewed in [3]). Tenascin-C is
expressed in the heart in the early embryo where it con-
tributes to the development of the myocardium, valves, and
coronary vessels [4, 5]. The heart develops normally in
tenascin-C knockout mice [5–7], suggesting that compen-
satory mechanisms for tenascin-C absence during
cardiogenesis exist. Tenascin-C is not found in healthy
adult heart tissues [8], except at the chorda tendineae of
papillary muscles [9] and at the base of valve leaﬂets [4].
However, it is re-expressed upon cardiac injury and is
found at high levels in a variety of cardiac diseases where
the level of expression appears to be a reliable biomarker of
disease progression and poor patient prognosis. Emerging
evidence has highlighted a number of novel roles for ten-
ascin-C during cardiac repair.
Tenascin-C expression during cardiac injury
Cardiac injury, for example damage and death of myo-
cardium caused by ischemia and oxygen deprivation during
MI, invokes an immediate repair response. Cardiac repair
proceeds via an acute inﬂammatory response to clear tissue
debris, followed by tissue deposition and remodeling,
which forms a collagenous scar to replace lost or damaged
tissue. Prompted by studies that demonstrated early and
transient expression of tenascin-C during inﬂammation and
Fig. 1 The modular structure of tenascin-C and the known binding
partners of each tenascin domain. Tenascin-C is a hexameric
extracellular glycoprotein. The appearance of puriﬁed tenascin-C
protein upon electron microscopy is shown. Each tenascin-C mono-
mer comprises four distinct domains: an assembly domain, EGF-L,
constant (grey) and alternatively spliced (black) FNIII repeats, and the
C-terminal FBG. The exon/intron structure of the human tenascin-C
gene on chromosome 9q33 is depicted schematically based on
analysis of sequence entries in the EMBL sequence data bank.
Tenascin-C-interacting molecules are shown at the bottom of the
ﬁgure. CALEB, chicken acidic leucine-rich EGF-like domain
containing brain protein; EGFR, epidermal growth factor receptor;
NaN, sodium channel subunit b2; RPTP f/b, receptor protein tyrosine
phosphatase f/b (image modiﬁed from Midwood and Orend 2010)
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123ﬁbrosis in dermal wound healing (reviewed in [1]), tenas-
cin-C localization during myocardial repair has also been
examined. Immunohistochemical analysis of myocardium
from patients from 6 h to 17 years following MI revealed
that tenascin-C was induced 4–6 days post infarction at the
edges of tissue injury. Expression shifted from the margin
to the center of the damaged area 2–3 weeks post-infarc-
tion and by 4 weeks, no tenascin-C was detected [8]. Thus
an early and transient expression of tenascin-C, returning to
basal levels by the time the collagen scar has formed, is
common to both dermal and myocardial injury. The
appearance of tenascin-C post MI paralleled that of ﬁbro-
nectin deposition with one exception; tenascin-C, but not
ﬁbronectin, was deposited around hibernating cardiomyo-
cytes [8], segments of the myocardium that are viable but
which exhibit reversible abnormalities in contractile func-
tion [10]. Tenascin-C and ﬁbronectin are frequently
coexpressed in diseased cardiac tissue as well as in tumor
angiogenesis (see below), which suggests that anti-adhe-
sive tenascin-C counteracts the adhesive functions of
ﬁbronectin and that both molecules function as accom-
plices in tissue remodeling (van Obberghen-Schilling et al.
2011).
Tenascin-C expression is also induced during mouse
[11] and rat [12] models of MI, as well as different types of
experimental cardiac injury such as myosin-induced myo-
carditis [13, 14], monocrotaline (MCT)-induced pulmonary
hypertension [15, 16], cerebral vasospam after aneurismal
subarachoic hemorrhage [17], and chronic cardiac rejection
[18]. Tenascin-C expression in experimental myocarditis
was sequentially documented and found to be up-regulated
very early following disease induction, appearing even
before cellular inﬁltration into areas of damaged tissue. It
was maintained during active remodeling at the periphery
of sites of cell necrosis where it associated with inﬂam-
matory foci, but was not found in subsequent scar tissue
[13]. Tenascin-C expression was also followed throughout
both acute and chronic models of MI. Murine reperfusion
induced MI (RMI) causes an acute inﬂammatory response
followed by rapid remodeling of myocardium and scar
formation. MI induced by cryo-coagulation (CMI) is also
followed by inﬂammation, but exhibits a prolonged
remodeling phase with delayed scar formation accompa-
nied by persistent macrophage and myoﬁbroblast
inﬁltration. Tenascin-C expression was rapidly induced in
RMI and down-regulated towards the end of ﬁbrosis.
However, expression was delayed in CMI and maintained
throughout the prolonged remodeling [11]. Tenascin-C was
also up-regulated in a porcine model of chronic ischemic
heart disease, but was not detected in the normal heart or in
acute disease [19].
The association of persistent tenascin-C expression with
prolonged inﬂammation and tissue remodeling is also
observed in human cardiac pathology. These data are
summarized in Table 1. In addition to its re-expression
during acute MI, tenascin-C is found at high levels in
diseases such as myocarditis, dilated cardiomyopathy,
hibernating myocardium, hypertension, and in end-stage
heart failure. Notably, in some of these conditions, tenas-
cin-C expression in heart tissue correlated with disease
activity. For example, tenascin-C was transiently expressed
in myocarditis but was not present in normal or healed
tissue. It speciﬁcally localized to sites of inﬂammation
where tissue levels correlated with the degree of lesion
severity [20]. Likewise, in dilated cardiomyopathy, tenas-
cin-C was associated with inﬂammatory cell inﬁltration
[21] and ﬁbrosis [22] but was not present in healed tissue
[21]. Higher tissue tenascin-C was detected in patients with
more chronic myocarditis [21].
Circulating tenascin-C levels have also been shown to
correlate with poor prognosis and mortality in MI, dilated
cardiac myopathy, and heart failure (Table 1). For exam-
ple, serum tenascin-C was elevated in patients following
acute MI compared to healthy controls, where it peaked 5
days following hospital admission. Follow-up studies
showed that tenascin-C levels remained higher in patients
that exhibited subsequent left ventricular (LV) remodeling,
a major predictor of morbidity and mortality, compared to
patients with no remodeling, and indeed was a useful
predictor of future adverse cardiac events [23]. Serum
tenascin-C levels were also higher in patients with dilated
cardiac myopathy compared to healthy individuals, and
correlated positively with the severity of heart failure, LV
dysfunction and tissue remodeling [24]. Serum tenascin-C
in patients with heart failure predicted future cardiac events
and correlated with larger LV end-diastolic volume and
higher mean pulmonary arterial pressure [25]. Similarly,
serum tenascin-C was increased in patients with idiopathic
cardiomyopathy in proportion to the severity of LV dys-
function [26]. Moreover, in patients with chronic kidney
disease, a risk factor for developing cardiovascular disease,
higher serum tenascin-C levels predicted associated cardiac
pathology [27].
Cardiac resynchronization therapy (CRT) following MI
has been shown to improve patient survival. Although the
mechanisms by which this occurs are not clear, CRT has
been shown to cause reversal of ventricular remodeling. In
patients that respond well to CRT, serum levels of tenas-
cin-C were signiﬁcantly reduced over 6 months [28].
Similarly, while angiotensin II induced hypertension in
mice and stimulated tenascin-C expression in ﬁbrotic
lesions, treatment with the aldosterone receptor antagonist
eplenerone attenuated inﬂammation and ﬁbrosis and
reduced tenascin-C expression [29].
Together, these data suggest that tenascin-C induction
occurs rapidly after cardiac injury where it associates with
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123inﬂammation and is maintained during tissue remodeling.
Its expression is down-regulated and is not present in
healed myocardium, but is found both in the tissue and
serum of patients with chronic heart disease where levels
correlate with prolonged cardiac ﬁbrosis. Circulating ten-
ascin-C may therefore provide an invaluable diagnostic
tool that will be particularly important in cardiac patholo-
gies where disease management can be deﬁned by
knowledge of likely poor progression. Treatments that
ameliorate cardiac remodeling also reduce tenascin-C
levels, suggesting that it can also be used to monitor tissue
repair and improvement in heart function. These data raise
a number of intriguing questions such as: what induces
tenascin-C expression upon cardiac injury?; what sustains
tenascin-C expression in heart disease?; what role does
tenascin-C play in cardiac repair and would targeting ten-
ascin-C expression or function constitute tractable targets
for treating cardiovascular inﬂammation and remodeling?
Regulation of tenascin-C expression in the heart
As part of an elegantly comprehensive study that examined
tenascin-C expression during murine myocarditis, Ima-
naka-Yoshida and collaborators identiﬁed cardiac
interstitial ﬁbroblasts as the major source of tenascin-C and
demonstrated that the large isoform is produced by these
cells [13]. Tenascin-C is also produced by interstitial
ﬁbroblasts in ﬁbrotic lesions in angiotensin II induced
hypertension [29]. The alternatively spliced domains that
are found within the large isoform of tenascin-C contain
cleavage sites for matrix metalloproteses (MMPs) [30].
Two recent studies investigated which ECM molecules
constitute in vivo substrates for MMP-7 [31] and MMP-9
[32] in mice after experimental MI. Proteomic screening of
LV infarct tissue revealed that tenascin-C fragments
increased in wild-type mice after MI but did not appear in
MMP-7 and MMP-9 null mice. These data indicate that
tenascin-C is a natural substrate for these proteases during
cardiac injury [31, 32]. Deletion of both these proteases
improves LV remodeling post MI, implying that MMP-
mediated degradation of ECM molecules such as tenascin-
C may contribute to excess ﬁbrosis during cardiac repair. In
addition, serum tenascin-C and plasma MMP-9 levels are
both elevated in patients with LV remodeling, and both are
reduced in patients that respond well to CRT-mediated
reversal of LV ﬁbrosis [28], suggesting that MMP-9
mediated cleavage of tenascin-C may also be relevant in
human pathology. Proteolytic cleavage of tenascin-C has a
number of functional consequences; namely modulation of
tenascin-C protein levels as well as exposure of cryptic
sites concealed within the full-length hexameric molecule.
Table 1 Tenascin-C expression in human cardiac pathology
Disease Tenascin-C expression Reference
Acute MI Transient protein expression; serum levels predict major
adverse cardiac events
[8, 23]
Acute pulmonary thromboembolism Plasma levels elevated [191]
Aortic aneurysm mRNA and protein elevated in vasa vasorum and aortic wall [192, 193]
CRT Serum levels fall in patients that respond well [28]
Cerebral vasospasm Serum levels increase transiently [17]
Chronic kidney disease After cardiac events, large splice isoforms in plasma correlate
with disease progression, predict mortality
[27]
Chronic hypertension Serum levels of B domain isoform elevated [194]
Dilated cardiomyopathy Transient protein elevation at sites of inﬂammation and
ﬁbrosis. Tissue and serum levels correlate with severity of
disease, predict future cardiac events
[21, 22][ 24, 25]
End-stage heart failure Plasma levels elevated [195]
Hibernating myocardium Protein elevated in hibernating myocardial segments [196]
Idiopathic dilated cardiomyopathy Serum levels increased in proportion to the severity of LV
dysfunction; tissue protein elevated
[19, 26]
Myocarditis Transient protein elevated in active inﬂammation; correlates
with severity of lesion
[20]
Myxomas Protein elevated in vascular cellular aggregations [197]
Pulmonary hypertension Plasma levels elevated [198]
Valvular heart disease and
coronary artery disease
A1 ? protein elevated in areas of interstitial and perivascular
ﬁbrosis; serum levels elevated and protein localizes to
basement membrane of rheumatic valves
[40, 199]
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123The latter can release or remove domains that mediate cell
adhesion [33, 34], as well as create or obscure binding sites
for other ECM components such as ﬁbronectin [35, 36].
However, the signiﬁcance of the generation of tenascin-C
fragments in cardiac pathology is not yet clear.
Many factors have been shown to induce tenascin-C
expression, including growth factors, inﬂammatory cyto-
kines, oxidative stress and mechanical stress (reviewed in
[37]). Of particular relevance to induction of tenascin-C
expression in the heart may be that mediated by mechan-
ical force (reviewed in [38]). Neonatal rat cardiac
myocytes subjected to mechanical deformation induced
tenascin-C mRNA and protein in an amplitude dependent
manner. This activation of tenascin-C expression involved
activation of the transcription factor NFjB but occurred
independently of PKC and MAPK activation. Mechani-
cally induced tenascin-C was attenuated by antioxidant
treatment, and could be independently induced by H2O2,
indicating a role for reactive oxygen species in tenascin-C
expression [39]. These ﬁndings suggest that tenascin-C
may participate in cardiac remodeling induced by
mechanical overload, such as hypertensive heart disease,
and that strain-induced reactive oxygen species may
potentiate tenascin-C expression. Most recently, serum
from patients with rheumatic valvular disease has been
shown to induce tenascin-C mRNA in aortic valve inter-
stitial cells. This induction was inhibited by neutralizing
antibodies to TNFa, and to a lesser extent to IFNc. Cyclical
strain also induced tenascin-C mRNA in these cells in a
manner that was dependent on the activation of Rho-kinase
but not ERK, p38 MAPK, or PKC. Together, cyclical strain
and TNF and IFNc synergistically induced tenascin-C
expression in interstitial cells [40]. Finally, in murine car-
diac ﬁbroblasts, tenascin-C expression was induced by
angiotensin II, TGFb1 and PDGF [29], suggesting that a
variety of stimuli combine to mediate tenascin-C expres-
sion upon cardiac damage.
The role of tenascin-C in cardiac injury
The site-speciﬁc localization of tenascin-C during cardiac
injury suggests that tenascin-C may play a role in both the
inﬂammatory and ﬁbrotic phases. Below we highlight the
ways in which tenascin-C has been shown to affect cardiac
function during repair and disease.
Cell adhesion
Tenascin-C has long been known to modulate cell adhesion
(reviewed in [2, 41]). It can promote the de-adhesion of
cells to the pro-adhesive ECM glycoprotein ﬁbronectin [42,
43] and causes down-regulation of focal adhesions [44, 45].
After coronary ligation induced MI in rats, interstitial
ﬁbroblasts expressed tenascin-C mRNA within 24 h, which
was down-regulated by 7 days and absent by 14 days.
In vitro, tenascin-C increased the number of cardiomyo-
cytes that attached to laminin but inhibited the formation of
focal contacts at costameres. These data suggest that syn-
thesis of tenascin-C after MI may serve to reduce the strong
adhesion of cardiomyocytes to connective tissue and
facilitate tissue reorganization [46]. In support of this, the
combined effects of increased tenascin-C mediated de-
adhesion with a down-regulation of integrin a6 in rat MI
may cause cardiomyocyte slippage, leading to adverse
ventricular remodeling [16]. Decreased cellular adhesion in
the presence of tenascin-C may explain its appearance
around hibernating cardiomyocytes post MI [8] where a
lack of traction may account for reduced contractile func-
tion observed in these areas.
Inﬂammation
Transient tenascin-C expression is often associated with
acute inﬂammation, and persistent tenascin-C with chronic
inﬂammation (reviewed in [1, 47]). In cardiac pathology,
tenascin-C is also associated with inﬂammatory foci [20,
21] and prolonged macrophage inﬁltration during chronic
murine MI [11]. Tenascin-C has been shown to exhibit pro-
inﬂammatory effects mediated by activation of Toll-like
receptor 4 in primary human and murine macrophages and
ﬁbroblasts [48] and via activation of a9 integrins in murine
macrophages [49], although its speciﬁc contribution to
cardiac inﬂammation is not known and warrants further
investigation.
Tissue remodeling
The majority of studies examining the role of tenascin-C
during cardiac injury have highlighted its role in new tissue
deposition or ﬁbrosis. Tenascin-C is expressed during the
active tissue remodeling phase of cardiac repair; a process
mediated by myoﬁbroblast differentiation and inﬁltration
into the damaged area [3]. A close relationship between
tenascin-C and myoﬁbroblasts has been documented in the
tumor stroma [50–52] and ﬁbrotic, contractile conditions
such as Dupuytren’s disease [53]. Persistent tenascin-C
expression is also associated with prolonged myoﬁbroblast
inﬁltration during chronic murine MI [11] as well as being a
reliable serum marker for adverse ventricular remodeling in
a number of human cardiac pathologies (Table 1). In
experimental murine myocarditis, tenascin-C deposition
preceded the appearance of myoﬁbroblasts [46], which cir-
cumstantially suggests that tenascin-C may induce
recruitment or differentiation ofthese specialized cells. This
issupportedbystudiesexaminingcardiacrepairintenascin-C
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123null mice. During MI induced by electrical injury, myocar-
dial repair proceeded normally in mice lacking tenascin-C
except that they exhibited delayed inﬁltration of myoﬁ-
broblasts into the myocardial interstitium; at sites of
necrosis, reduced myoﬁbroblast numbers were detected 1
and2dayspostMI,butlevelsrecoveredtoresemblethosein
wild-typemice by3days.Nodefect wasobservedincardiac
ﬁbroblast proliferation in heart tissue, suggesting that the
reduced number of myoﬁbroblasts is not due to tenascin-C
promotion of cell proliferation. Indeed, closer in vitro
examination of cardiac ﬁbroblasts demonstrated that cells
isolated from tenascin-C null mice exhibited reduced
transmigration, lower expression of the myoﬁbroblast dif-
ferentiation marker a-smooth muscle actin and collagen
contraction, all defects that could be rescued by the addition
ofexogenoustenascin-C.Thesedataindicatethattenascin-C
expression during cardiac injury drives myoﬁbroblast
migration, differentiation, and contraction. Moreover, the
alternatively spliced FNIII repeats and FBG domain were
shown to stimulate cardiac ﬁbroblast migration and differ-
entiation, suggesting that these domains are responsible for
the observed tenascin-C effects [54]. A second study
examined the response of tenascin-C null mice to MI
induced by permanent coronary ligation. Consistent with
data from other models, in wild-type mice tenascin-C
mRNA was up-regulatedat1day, down-regulated by 7days
and not present by 14 days, whereas protein appeared at 1
day, peaked in the developing granulation tissue at 5 days
and was subsequently down-regulated over time until 28
days when none was detected. An extremely thorough
examination of these mice revealed no histological differ-
ences ingranulation tissue formationbetweenwild-type and
tenascin-C null mice, nor were there any signiﬁcant differ-
encesinrateofanimalmortalityorinfarctsize.However,the
end-diastolic pressure and dimension, and myocardial
stiffness, were lower in tenascin-C null mice. In addition,
quantitativeanalysisofthepercentageofinterstitialcollagen
volume in the residual myocardium revealed that matrix
deposition was signiﬁcantly reduced in mice that do not
express tenascin-C. This accelerated adverse ventricular
remodelingandﬁbrosisinthemyocardiuminthepresenceof
tenascin-C suggests that it plays an important role in driving
LV remodeling [55].
The molecular mechanisms by which tenascin-C may
exert these affects on heart repair are not clear and are
likely to be extremely complex. There is evidence that
tenascin-C is closely linked to TGFb-mediated ﬁbrosis.
Tenascin-C expression is induced by TGFb in cultured
cardiac ﬁbroblasts [20]. In addition, loss of smad3 resulted
in a similar phenotype to that described in the tenascin-C
null mice; smad3 null mice exhibit attenuated diastolic
function and reduced interstitial ﬁbrosis that was associated
with decreased tenascin-C and collagen deposition [56].
These data suggest some interplay between TGFb and
tenascin-C signaling pathways. However, in smad 3 null
mice, myoﬁbroblast numbers were increased, in contrast to
tenascin-C null mice, which exhibited a transient delay in
myoﬁbroblast population of injured myocardium. This
implies a speciﬁc, TGFb-independent, role for tenascin-C
in myoﬁbroblast regulation and a common role in pro-
moting tissue deposition for tenascin-C and TGFb. Another
player in TGFb signaling has been linked to tenascin-C
expression during cardiac injury in vivo. Loss of smad8
function in mice results in spontaneous changes in distal
pulmonary arteries including medial thickening and
smooth muscle hyperplasia that is observed in patients with
pulmonary artery hypertension. This is accompanied by
increased tenascin-C expression [57].
Tenascin-C expression has also been shown to drive
ﬁbrosis in response to other types of tissue injury and in
other murine models (reviewed in [1]). In particular, during
immune-mediated hepatitis, collagen type I transcription
was attenuated in tenascin-C null mice. These mice also
exhibited lower numbers of activated myoﬁbroblasts as well
as reduced TGFb mRNA [58]. Moreover, tenascin-C null
mice exhibit exacerbated renal ﬁbrosis upon snake venom-
induced glomerulonephritis. Here, the induction of TGFb
and PDGF was delayed, and levels of collagen and ﬁbro-
nectin deposition were reduced [59]. Together, these data
indicate that during tissue repair, tenascin-C can be induced
by TGFb but it also induces the expression of TGFb itself.
This positive feedback loop may mediate the promotion of
collagen transcription and deposition. Moreover, tenascin-C
may also affect how cells respond to pro-ﬁbrotic growth
factors, in addition to controlling their tissue levels. In vitro,
mesangial cells isolated from tenascin-C null mice failed to
proliferate in response to PDGF or TGFb,i nc o n t r a s tt o
wild-type cells [59]. These data suggest a global role for
tenascin-C in mediating ﬁbrosis upon tissue injury and raise
the question why tenascin-C levels are increased during
excessive ﬁbrosis, for example that associated with cardiac
pathology. It may be that tenascin-C is persistently induced
as a repair mechanism that fails to keep up with increasing
damage or that increased tenascin-C itself causes increased
damage. These data also highlight the potential of targeting
tenascin-C action in order to reduce aberrant ﬁbrosis. Based
on the success of strategies that reduce pro-ﬁbrotic TGFb
isoforms in ameliorating collagen deposition and scar for-
mation [60, 61], this approach may prove extremely
valuable.
Tenascin-C and atherosclerosis
The most common cause of MI is coronary artery occlusion
following the build-up or rupture of atherosclerotic
3180 K. S. Midwood et al.
123plaques. Tenascin-C is expressed during arterial wall injury
and accumulating evidence demonstrates that it contributes
to both plaque formation and rupture. These data suggest
that, in addition to a direct role in mediating cardiac
inﬂammation and ﬁbrosis, tenascin-C may also contribute
to one of the major causes of cardiovascular disease.
Tenascin-C expression in the vasculature
Arterial expression of tenascin-C has been examined in
experimental models of vascular injury. For example,
tenascin-C protein was observed in the intimal layer of the
walls of uninjured rat aorta and carotid artery, but was not
found in the media. Upon balloon catheter-induced injury,
tenascin-C was up-regulated speciﬁcally in the neointimal
lesion where it was associated with the ECM of prolifer-
ating smooth muscle cells (SMC) [62]. Tenascin-C protein
and mRNA expression were transiently induced during
murine neointimal hyperplasia caused by abdominal aor-
totomy. After aortic suture, tenascin-C was observed by 7
days in the media and periadventitia around the suture line,
staining increased by 14 days in the neointima and media
but was not detected by 28 days [63]. Grafting of abdom-
inal arteries to carotid arteries also causes neointimal
hyperplasia in mice. Here, tenascin-C expression was
transiently induced in the media and intima of both the
donor and recipient vessel 14 days after transplantation
[64]. Tenascin-C expression was also induced in athero-
sclerotic plaques formed in the arteries of apoE null mice
on a high-cholesterol diet [65]. Interestingly, in rat models
of MCT-induced hypertension, tenascin-C was expressed
in the central and peripheral pulmonary arteries in the
adult, but not in infant vessels. The latter tissues sponta-
neously repair vascular lesions where adult tissues do not
[66]. These data suggest that, as with many other types of
tissue injury, transient tenascin-C expression is induced
upon vascular damage and is down-regulated and cleared
from the tissue after repair is complete. They also imply
that lack of tenascin-C may be associated with improved
vessel repair outcomes.
Persistent expression of tenascin-C is associated with
human arterial pathology, the best-studied example of
which is atherosclerosis. Wallner and collaborators ﬁrst
demonstrated tenascin-C expression in human atheroscle-
rotic plaques where levels appeared to increase with plaque
progression. Minimal staining was observed in early
ﬁbrous plaques, but high levels were found in lipid rich
plaques, both in and around the lipid core. In two ruptured
plaques, strong tenascin-C staining was localized to the
area of rupture. Tenascin-C speciﬁcally localized to areas
of macrophage accumulation in plaques that were heavily
inﬁltrated with immune cells, but was absent from the
SMC-populated adventitial and medial layers [67]. Ten-
ascin-C expression also correlated with ruptured plaques in
patients with acute coronary syndromes. Tenascin-C was
found in all plaques obtained from patients with stable
angina or acute coronary syndromes. However, quantiﬁ-
cation of the area of tenascin-C immunoreactivity revealed
that staining was highest in areas adjacent to thrombus
formation and in plaques with inﬂammatory inﬁltrate and
intra plaque hemorrhage [68]. Differential expression of
tenascin-C during atherosclerosis was conﬁrmed by anal-
ysis of the gene expression proﬁle of human aortas with
varying degrees of atherosclerotic disease by microarray
[69]. In fact, most studies have compared tenascin-C
expression in arteries with different stages of disease, likely
due to tissue availability. However, in some studies, human
mammary artery was used as a control and tenascin-C
expression was found to be absent [67]. This lack of ten-
ascin-C expression in mammary arteries was conﬁrmed by
Qin and collaborators. Using subtractive hybridization,
they examined gene expression in porcine arteries that are
prone to developing atherosclerosis (coronary) and those
that are athero-resistant (mammary). Tenascin-C was
among those genes that were preferentially detected in
normal coronary arteries, along with lipid retention, growth
and inﬂammation genes [70]. These data suggest that basal
levels of tenascin-C are present in normal athero-prone
arteries. Most adult arteries will likely have suffered some
arterial insult over time, so it may be hard to deﬁne a truly
‘normal’ level of tenascin-C expression in coronary arteries
without examining fetal or juvenile tissue.
Increased tenascin-C expression in coronary artery ath-
erosclerotic lesions was found to be associated with
increased TGFb, higher numbers of macrophages and
TUNEL-positive cells in diabetic patients that succumb to
acute MI [71]. The accumulation and subsequent oxidation
of LDL in the arterial wall is key to the development of
atherosclerosis. The release of aldehydes from this reaction
has been shown to modify ECM components including
ﬁbronectin and tenascin-C: autoantibodies to aldehyde-
conjugated ﬁbronectin and tenascin-C were found in the
plasma from atherosclerotic patients [72]. A recent study
also examined the prevalence of 35 tenascin-C SNPs in
three independent cohorts of patients with atherosclerosis
and cardiovascular disease (n = 205, n = 1,325, n = 879,
respectively). Three SNPS were found to be in high linkage
disequilibrium and associated with high risk of athero-
sclerosis in all data sets. Of these, one coding SNP was
located in TNfnIII8, which in combined analyses was sta-
tistically signiﬁcant [p = 5 9 10 (-6)]. Although
synonymous, it was proposed that this may potentially
affect tenascin-C function by affecting mRNA structure
and stability or splicing efﬁciency, even in the absence of
any amino acid sequence alteration. Interestingly, this SNP
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ques [73], consistent with reports that tenascin-C
expression peaks during late-stage disease and plaque
rupture. Additional genetic evidence reveals that the ten-
ascin-C gene is located within a quantitative trait locus
(Ath8) that inﬂuences the difference in susceptibility to
atherosclerosis between the NZB/BINJ and SM/J mouse
strains [74].
In addition to atherosclerosis, tenascin-C expression has
also been reported in the adventitia media of human vein
grafted arteries but not in normal veins [75] and transient
induction observed in arterial walls followed over time
after coronary artery bypass grafting-induced stenosis [76].
Together, this body of evidence suggests that tenascin-C
expression is transiently induced upon arterial injury, but is
persistently expressed during arterial disease increasing
towards the advanced stages of atherosclerotic plaque
development, where expression correlates with inﬂamma-
tion and plaque rupture.
The role of tenascin-C in atherosclerosis
Upon arterial injury, for example that caused by a high-fat
diet, changes in the endothelium allow immune cell
adhesion and transmigration into the vessel wall intima.
Inﬁltrating cells such as macrophages and T lymphocytes
activate the proliferation of SMC in the adventitia, which
migrate into the developing intimal plaque site. Together
with invading myoﬁbroblasts, SMC mediate excessive
ECM deposition that propagates plaque growth. The
expansion of the plaque increasingly occludes vessel blood
ﬂow, and as it matures and calciﬁes it can rupture enabling
thrombosis to occur [77, 78]. Below we highlight how
tenascin-C has been implicated in the development and
progression of atherosclerosis by taking part in a number of
these different processes.
The source of tenascin-C during vascular injury
A number of cell types from distinct lineages are impli-
cated in producing tenascin-C during arterial injury. Based
on the co-localization of tenascin-C protein and mRNA
with inﬁltrated macrophages in human atherosclerotic
plaque sections, Wallner and collaborators examined ten-
ascin-C expression in this cell type. A small form of
tenascin-C (7-kb transcript, 220-kDa protein) was consti-
tutively expressed by human monocyte-derived
macrophages [67]. Consistent with data that identify
macrophages as a source of tenascin-C, we also demon-
strated that tenascin-C is produced by primary human
macrophages [79]. It was also demonstrated by in situ
hybridization during balloon-induced rat and porcine arte-
rial injury, that tenascin-C was expressed 3 days after
injury by adventitial myoﬁbroblasts [80]. The association
of tenascin-C with this cell type has been discussed in
previous sections of this review.
In rat models of MCT induced hypertension, tenascin-C
expression correlated with proliferating SMC [66]. Hedin
also proposed the source of tenascin-C during experimental
arterial damage to be SMC based on its association with
proliferating a-smooth muscle actin-rich cells during bal-
loon catheter injury. Primary rat aortic SMC have been
shown to assemble tenascin-C ﬁbrils in culture [62] and
tenascin-C expression in cultured rat aortic SMC can be
induced in response to a number of different stimuli. PDGF
[67] and angiotensin II [81] both induce a large and small
form of the protein (7- and 8.4-kb transcript, 220- and
280-kDa protein). SMC isolated from newborn rat aortas
speciﬁcally express a tenascin-C isoform containing the
alternatively spliced domains A1 and A2. This isoform is
upregulated by PDGF but is down-regulated in adult rat
aortic SMC, where it re-appears only after carotid injury
[82]. Mechanical strain also induced tenascin-C expression
in SMC. Microarray analysis of primary human vascular
SMC exposed to biphasic axial strain revealed that only
three transcripts out of 5,000 assessed were induced[2.5-
fold: cyclooxygenase-1, tenascin-C, and plasminogen
activator inhibitor-1. These data suggest that a highly
speciﬁc response of this cell type to the strain [83]. Pul-
monary blood ﬂow also regulates tenascin-C expression.
Ligation of porcine pulmonary arteries increased tenascin-
C expression, suggesting that the hemodynamic changes
are key in modulating arterial ECM remodeling [84].
Other studies showed that tenascin-C expression is
regulated in rat aortic SMC by the structural state of the
cell environment. Culturing cells on native ﬁbrillar type I
collagen suppressed tenascin-C expression, whereas MMP-
proteolyzed or monomeric/denatured collagen induced
transcription. These differential responses are mediated by
the ligation of distinct receptors by each type of ECM;
avb3 integrin-mediated MAPK activation was able to
induce tenascin-C expression by digested matrices but
ligation of a2b1 integrins by intact collagen did not [85].
Tenascin-C up-regulation in hypertensive arteries corre-
lated with the expression of the homeobox transcription
factors Prx1 and Prx2. In rat aortic SMC cultured on
denatured collagen, induction of Prx1 and Prx2 was high
compared to that in cells cultured on native type I collagen.
Over-expression of Prx1 signiﬁcantly induced SMC growth
as well as tenascin-C expression, suggesting that regulation
of tenascin-C expression by the physical organization of
the ECM is mediated by Prx family members [86].
Coincident with increased tenascin-C expression on
denatured collagen, SMC exhibit an altered morphology,
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geometric changes in cell shape were found to dictate
tenascin-C expression; as cells rounded, tenascin-C
expression dropped. RhoA- and ROCK-mediated cyto-
skeletal architecture formation was shown to be
responsible for creating a cell morphology that is permis-
sive for ERK-dependent tenascin-C expression in cultured
SMC. Moreover, ROCK inhibition suppressed the expres-
sion of tenascin-C by SMC in hypertensive rat pulmonary
arteries [87]. These data suggest that RhoA and ROCK,
factors which also regulate vasoconstriction in pulmonary
hypertension, may couple vessel contraction with ECM
remodeling and cellular architecture.
Tenascin-C and smooth muscle cell function
The detailed examination of tenascin-C expression in SMC
has been paralleled by investigation into the potential
functional relevance of its up-regulation in this cell type,
and the evidence points predominantly to a role in medi-
ating neointimal hyperplasia.
SMC migration and proliferation are both key features
in plaque development. Tenascin-C expression during
experimental arterial injury in vivo was associated with a
change in SMC phenotype from a non-proliferative phe-
notype to a migratory, synthetic state [62]. Cell migration
relies on dynamic adhesion and de-adhesion to the under-
lying substratum. Both SMC derived from adult and
newborn rats adhered to a tenascin-C substrate, although
newborn cell adhesion was threefold greater than that of
adult cells. SMC did not spread on tenascin-C in contrast to
cells plated on ﬁbronectin. This interaction was RGD-
dependent and shown to be mediated by 30 amino acids
within the FBG domain of tenascin-C [88]. This region was
later shown to bind to avb3 integrins [89]. In addition,
tenascin-C inhibited the adhesion of human and rat SMC to
ﬁbronectin [90]. These data collectively suggest that ten-
ascin-C may modulate or destabilize SMC attachment to
the ECM during migration. Tenascin-C isoforms contain-
ing the A1A2 domains also promoted SMC chemotaxis in
vitro [82], suggesting that the splice variants that are spe-
ciﬁcally up-regulated by SMC during arterial injury may
also directly attract further SMC to the injury site.
A series of papers from Jones and collaborators exam-
ined the role of tenascin-C in modulating SMC response to
different growth factors. Culturing rat SMC on tenascin-C
enhanced cellular growth upon stimulation with bFGF and
was essential for proliferation in response to EGF [66]. In
lung biopsy tissue from patients with congenital heart
defects and pulmonary hypertension, the distribution of
tenascin-C, EGF, and proliferating cell nuclear antigen
strongly overlapped in obstructive lesions [91]
circumstantially linking tenascin-C and EGF-mediated cell
growth in vivo. Tenascin-C ligation of avb3 integrins was
shown to mediate focal adhesion formation that contained
clusters of activated EGF receptor molecules, and cross-
linking avb3 integrins was sufﬁcient to replicate the effect
on plating cells on tenascin-C substrates [92]. Similarly,
most recently, rat SMC cell lines plated on a tenascin-C
substrate exhibited enhanced proliferation and migration in
response to PDGF. Cells grown on tenascin-C exhibited
increased phosphorylation of PDGF receptor beta and
clustering of av integrins and activated FAK and src at
focal adhesions [93]. Together, these data indicate that
crosstalk between integrin and growth factor receptors can
amplify cell proliferation and migration upon activation
with their cognate ligands; growth factors such as PDGF or
EGF and tenascin-C.
SMC apoptosis is a key feature of the later stages of
atherosclerotic plaque development [94]. Despite an asso-
ciation with tenascin-C and SMC proliferation described
above, tenascin-C also co-localized to TUNEL-positive
cells in human atherosclerotic lesions [71]. A later study
showed that cultured human SMC can degrade full-length
tenascin-C substrates to yield fragments that were detected
with an antibody against the EGF-L repeats. EGF-L-con-
taining fragments were also detected in human
endarterectomy specimens. Recombinant EGF-L induced
apoptosis in SMC via activation of caspase-3, where intact
tenascin-C and its other constituent domains did not affect
cell viability [95]. These data suggest that while intact
tenascin-C may drive SMC survival in atherosclerosis,
towards the end stages of plaque formation, tenascin-C
degradation releases cryptic fragments that mediate SMC
apoptosis.
Modulating tenascin-C expression and function
during vascular disease
A number of studies examining vascular injury and disease
in mice with targeted deletions in tenascin-C or the effect
of ablating tenascin-C expression have conﬁrmed an
important role for this ECM glycoprotein in mediating
neointimal hyperplasia by stimulating SMC proliferation
and migration, as well as enhancing ECM deposition.
Tenascin-C null mice are refractory to experimental
neointimal hyperplasia induced by aortotomy. Quantita-
tively less hyperplasia was observed in these animals
compared to wild-type mice, and this was accompanied by
a lower proliferating cell nuclear antigen index and less
proteoglycan deposition [63]. Grafting aortic segments
from tenascin-C null mice into null recipients signiﬁcantly
reduced neointimal hyperplasia and SMC proliferation
compared to wild-type grafting [64]. Similarly, in a distal
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tenascin-C expression was induced over time in the media
and neointima of the graft body in rat abdominal aortas.
Local application of the cAMP phosphodiesterase inhibitor
cilostazol around the graft was found to reduce neointimal
hyperplasia and cell proliferation as well as to suppress
tenascin-C expression [96].
Organ cultures of hypertrophied rat pulmonary arteries
progressively thicken and exhibit cellular proliferation and
ECM accumulation, providing a good ex vivo model sys-
tem with which to assess neointimal hyperplasia. In these
cultures, antisense inhibition of tenascin-C expression
arrested arterial thickening by inducing SMC apoptosis.
However, cultures with silenced tenascin-C did not com-
pletely regress as expansion of an SMC population
expressing an alternative avb3 survival ligand, osteopontin,
compensates for loss of tenascin-C [97]. These data suggest
that inhibition of tenascin-C, in combination with other
inducers of SMC survival, may represent a promising
strategy for the prevention of neointimal thickening during
atherosclerosis and bypass grafting.
Tenascin-C and thrombosis
In thrombosis, platelet-mediated formation of a ﬁbrin-rich
blood clot is a key response to wound healing, but also
contributes to luminal narrowing of the arteries during
atherosclerosis. It occurs in arteries with advanced disease
that have signiﬁcantly narrowed lumens or altered blood
ﬂow and causes further artery blockage. It is hypothesized
that these arterial walls become rich in platelet adhesive
substrates. Tenascin-C was recently shown to support the
adhesion of platelets in vitro under both static and shear
ﬂow conditions. This interaction was mediated primarily
by a2b1 integrins in static culture, but additionally required
the GPIb-IX complex, and to a lesser extent aIIbb3 inte-
grins, under ﬂow. Von Willebrand factor (vWF), a known
ligand for GPIb-IX, was shown to be required for GPIb-IX
binding to tenascin-C and a direct interaction between
puriﬁed vWF and tenascin-C was demonstrated [98]. These
data identify a number of novel binding partners for ten-
ascin-C. Moreover, the adhesion of platelets to tenascin-C
resulted in their activation [98], suggesting it may provide
an ECM that is permissive for thrombosis. Given the high
levels of expression of both tenascin-C and vWF in ath-
erosclerotic plaques, platelet activation by these molecules
may also promote thrombus formation during late athero-
sclerosis. Tenascin-C expression in advanced plaques lies
close to areas of plaque rupture and thus may be exposed to
circulating platelets. The success of antithrombotic drugs
such as aIIbb3 blockers has been tempered by side-effects
that include increased risk of bleeding. Tenascin-C null
mice exhibit normal hemostasis [98], suggesting that a
strategy targeting tenascin-C-mediated thrombosis may
enable uncoupling of hemostasis from thrombosis to pre-
vent arterial narrowing with fewer side-effects.
Another way in which tenascin-C might contribute to
ﬁbrin-mediated luminal occlusion is by triggering ﬁbrin
accumulation via down-regulation of tissue plasminogen
activator. In comparing the gene-expression proﬁles of
embryonic ﬁbroblasts isolated from wild-type or tenascin-C
null mice, the group of Chiquet-Ehrismann identiﬁed tissue
plasminogen activator as the most consistently over-
expressed gene in tenascin-C-deﬁcient cells. In the absence
of tenascin-C, cellular digestion of a ﬁbrin-agarose matrix
was enhanced. Moreover, during lung inﬂammation and
ﬁbrosis induced by bleomycin, tenascin-C accumulated in
areas of ﬁbrin deposition, as well as in the lungs of asth-
matic patients and in lung tumors and head and neck
carcinomas [99]. This is consistent with reports of tenascin-
C in ﬁbrin-rich deposits in synovium from RA patients
[79]. These data suggest that tenascin-C acts as a regulator
of ﬁbrin deposition by negative transcriptional control of
tissue plasminogen activator, and this enables ﬁbrin accu-
mulation during arterial injury.
Tenascin-C-MMP feedback loops in vascular disease
Throughout the vascular pathology literature there is a
recurring link between tenascin-C and MMPs. Several of
these proteases are thought to be key players in mediating
plaque rupture [99]. Increasing tenascin-C expression also
correlates with increasing plaque instability, and this
together with the fact that macrophages are one of the
major sources of tenascin-C in the atherosclerotic plaque
prompted Wallner and collaborators to examine MMP
synthesis by RAW macrophages in response to tenascin-C.
These cell lines, when cultured on a tenascin-C substrate
for 24 h, demonstrated increased MMP9 activity [67]. This
group also showed that tenascin-C stimulates MMP-2
expression and gelatinolytic activity in cultured SMC [95].
MMPs have also been linked to the induction of tenascin-
C expression. The pan-MMP inhibitor GM6001 suppressed
tenascin-Cexpression inrat SMC cultured on native ﬁbrillar
type I collagen, although induction of tenascin-C expression
by cells on denatured collagen was MMP-independent.
Tenascin-C and MMP-2 levels were high in cells seeded in
attached collagen gels, but in ﬂoating collagen gels, tenas-
cin-C expression was suppressed, concomitant with
suppressed MMP-2 levels [92]. Likewise, tenascin-C and
MMPexpressionwaslinkedinarteryorgancultures.Normal
porcine pulmonary arteries embedded in attached collagen
gels exhibited increased activity of MMP-2 and MMP-9 as
well as tenascin-C. In contrast, arteries cultured in ﬂoating
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sion. Hypertrophic arteries exhibited the same trend of
protein expression in ﬂoating and attached gels, albeit with
higher overall levels of MMP-2 and tenascin-C. Culture of
arteries in ﬂoating gels was accompanied by cell apoptosis
and regression ofthe thickenedmediaofhypertropic vessels
[100]. In further studies, treatment of hypertrophied rat
pulmonarystudieswithserineelastaseinhibitorsorGM6001
induced regression, an effect that was associated with
reduced tenascin-C expression [97]. Human calciﬁc aortic
stenosis cusps exhibit a co-localization of tenascin-C and
MMP-2depositionandMMP-2activity,wheredepositionof
these proteins appears to be linked to areas of calciﬁcation
[101]. Tenascin-C, MMP-2 and MMP-9 expression also
coincide in subdermal elastin implants that undergo calciﬁ-
cation in vivo. The MMP inhibitor BB-1101, when injected
systemically or locally into the implant, was extremely
effective in suppressing tenascin-C expression. Elastin cal-
ciﬁcation was also reduced after treatment with BB-1101
[102]. These data suggest that targeting MMP-mediated
tenascin-C induction may provide a useful point of inter-
vention in vascular disease.
It is not clear how MMPs induce tenascin-C expression,
or vice versa, during vessel injury in vivo. Tenascin-C
induction may result from direct stimulation of gene
expression by MMPs or indirectly via MMP regulation of
the extracellular environment; as described above, MMP
digested type I collagen is effective at stimulating tenascin-
C transcription [85]. Finally, MMPs also cause fragmen-
tation of tenascin-C [30]. Speciﬁcally, SMC produce
pro-apoptotic tenascin-C fragments the generation of which
could be prevented by inhibition of MMP activity with the
pan-inhibitor GM6001 [95]. Thus MMPs can mediate
post-translational control over tenascin-C activity, in addi-
tion to regulating the transcription of this gene, which in
turn may induce further MMP expression and activation.
Thus, a positive feed-forward loop may result that drives
plaque progression, destabilization, and eventual rupture.
Tenascin-C in stem cell biology
In addition to the advances in our understanding of tenas-
cin-C in cardiac and arterial biology and pathology,
investigations into the role of tenascin-C in stem cell
biology are also gathering pace, particularly in the central
nervous system (CNS) and in the context of tumorigenesis.
Tenascin-C in neural stem cells
Studies have reported several CNS-speciﬁc abnormalities
in the tenascin-C null animals [103, 104]. Phenotypic
differences were reported, depending on the genetic
background of the mouse strains used for analyses: while
the migration of oligodendrocyte progenitors (OP) from
mice which do not express tenascin-C was always
enhanced, when compared to their heterozygous counter-
parts, in C57BL6 J/CBA mice. However, this was not
always observed in strain 129 mice [103]. Tenascin-C was
also shown to regulate a mitogenic response in OP, a role
dependent on integrin avb3 and PDGF signaling [103].
Moreover, signiﬁcant reductions in the number of radial
glial cells (RC2 ? cells, a subset of stem cells in the
embryonic CNS) were observed throughout the develop-
ment of the CNS at E13.5, E18.5, and immediately upon
birth at P0 [104]. Neural stem cells (NSC) were isolated
form murine CNS and grown as neurospheres in vitro. NSC
neurospheres from tenascin-C null mice derived from
E10.5 rostral telencephalic vesicles were FGF2 responsive
but unresponsive to EGF [104]. When neurospheres were
established from newborn animals (P0), tenascin-C null
cells were more numerous but smaller than the ones
derived from wild-type animals. In addition, these tenas-
cin-C null neurospheres were less responsive to FGF2, but
responded similarly to EGF stimulation. Differentiation
assays indicated that the three lineages (neurons, astro-
cytes, and oligodendrocytes) could be formed from
tenascin-C null NSCs in vitro. A few phenotypical differ-
ences between cells derived from wild-type or null mice
were however observed and concerned the formation of
longer cellular processes of oligodendrocytes and an
increased number of neurons. The addition of exogenous
tenascin-C to the culture medium speciﬁcally reverted the
enhanced neuronal differentiation of tenascin-C null cells.
Altogether, this shows that tenascin-C is dispensable for
the maintenance of NSC, but is still implicated in the
control of NSC fate choices (self-renewal/proliferation and
differentiation) and the migration and differentiation of
their progeny.
More recently, in vitro differentiation of embryonic
stem cells (ESC) to NSC using retinoic acid followed by
differentiation into neurons and astrocytes revealed that
tenascin-C is induced together with proteoglycans, glypi-
can-1, and RPTP f/b (a receptor for tenascin-C) in both
NSC and differentiated cells [105]. This suggests that when
in vitro models of NSC are used, tenascin-C seems to play
important roles in regulating mechanisms controlling NSC
self-renewal and differentiation.
At the molecular level, recent progress has also been
made and sheds new light on the complexity of the
downstream mechanisms that tenascin-C regulates in NSC.
Von Holst and coworkers found that 20 different tenascin-
C isoforms generated by alternative splicing are expressed
in neurospheres in vitro [106]. Furthermore, using proteo-
mics-based approaches, it was shown that tenascin-C is
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NSC [107]. The HNK-1 epitope (Human Natural Killer-1,
aka CD57) consists in a trisaccharide and a terminal glu-
curonyl residue and was mostly found on the largest
isoforms of tenascin-C [107]. From a functional perspec-
tive, the HNK-1 post-translational modiﬁcation promotes
tenascin-C-dependent NSC proliferation via the EGFR and
the Ras/MAPK (ERK1/2) pathways [107].
A novel function of tenascin-C was also uncovered by
von Holst et al. [108], who showed that tenascin-C can
reduce the expression of Sam68, a member of the STAR
protein family. Sam68 is a well-known signaling adaptor of
various receptors [109] and a RNA-binding molecule that
regulates different steps of mRNA processing, depending
on the cellular context [110]. Conversely, upon its over
expression, Sam68 can also modulate tenascin-C mRNA
splicing, which could represent a signaling feedback
mechanism by inducing the largest isoforms of tenascin-C
mRNAs that contained 5–6 type III FN repeats [108].
Mechanistically, tenascin-C inhibits OP differentiation and
is able to bind contactin and Fyn, localized at oligoden-
drocyte membrane rafts [111]. Hereby, tenascin-C leads to
reduced Akt phosphorylation and reduced expression of
both myelin basic protein and Sam68 in a PI3kinase
pathway-dependent manner [111]. These studies provide a
new mechanism by which tenascin-C, via Sam68, may
control signal integration, cellular adaptation, and decision-
making by NSC and their progeny. Therefore, the further
characterization of the roles and the targets downstream of
tenascin-C and Sam68 on a genome-wide scale in relevant
cellular contexts represent exciting and novel opportunities
potentially leading to broader applications.
Tenascin-C in tumor-derived endothelial cells
It was recently demonstrated that glioblastoma (GBM)
stem cells can transdifferentiate into microvascular endo-
thelial cells and form functional vessels within GBM [112,
113]. While it is currently unknown whether these cells
express tenascin-C, it was reported that peri-vascular pro-
genitors and tumor-derived endothelial cells (TEC) can
also be observed in neuroblastoma (NB) patient samples
and cell lines [114]. These peri-vascular progenitors and
TEC speciﬁcally express both Oct-4 (a stem cell marker
and master regulator of pluripotency in ESC) and tenascin-
C[ 114]. Importantly, the tumor origin of the Oct4 ? cells
was assessed by showing that N-myc gene ampliﬁcation, a
well-known genetic aberration and hallmark of NB tumor
cells, is detected in the genome of these cells. In addition,
the authors sorted tenascin-C? and—NB cells from cell
lines and assessed their differential capacities. In vitro,
tenascin-C ? NB cells had the capability of growing as
neurospheres while tenascin-C- cells could not [114].
In vivo upon orthotopic xenografting in nude mice, cells
with both immunophenotypes formed tumors; however, the
tumors derived from tenascin-C? cells had a signiﬁcantly
larger volume and harbored TEC and tumor-derived ves-
sels [114]. No tumor-derived vessel was indeed observed in
the (smaller) tumors derived from the tenascin-C- NB cells
[114]. These latter observations suggest that tenascin-C
may not be important to confer tumor-initiating properties
to NB cells but rather is crucial to promote tumor growth
and progression by sustaining aberrant and tumor cell-
derived angiogenesis.
Altogether, these studies support the notion that tenas-
cin-C may play key roles in promoting brain tumor
progression by stimulating angiogenesis through the
establishment of tumor cell-derived vessels. This property
of tumor cells to transdifferentiate into endothelial cells
could represent a speciﬁcity of gliomas and neuroblasto-
mas, and hereby represent a molecular reminiscence of
their developmental original neural phenotype. NSC
themselves are indeed able to transdifferentiate into
endothelial cells, on the contrary to most epithelial adult
tissue-speciﬁc stem cells for example. It will be therefore
of interest to further characterize the generality of this
recently uncovered capacity of tumor cells, the function-
ality of tumor-derived blood vessels, and the implication of
tenascin-C in the control of this transdifferentiation
process.
Tenascin-C in melanoma cancer stem cells
In melanoma cell lines, it was recently shown that tenascin-
C expression is induced when cells are grown as spheres in
vitro and that tenascin-C knock down diminished cell
proliferation speciﬁcally when the cells were grown as
spheres [115]. In vitro culture of tumor cells as spheres is
known to enrich for and propagate cells with tumor-initi-
ating properties. Upon subcutaneous grafting of these cells
into immuno-compromised NOD/SCID mice, tenascin-C
knock down melanoma cells were not impaired in primary
tumor formation and growth. However, upon intravenous
injections of the same cells, lung colonization and metas-
tasis formation were severely impaired for tenascin-C
knock down melanoma cells [115]. Moreover, tenascin-C
seems to be important in maintaining the side population
(SP) fraction of melanoma cells in the spheres in vitro:
tenascin-C knock down indeed diminished the fraction of
SP cells, which represent a subpopulation of cancer cells
that efﬁciently efﬂux drugs, via the up-regulation of ABC
transporters, ABCB5 in this case [115]. Hereby, tenascin-C
knock down potentiated the action of doxorubicin in
inducing melanoma cell apoptosis, while the addition of
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to the drug [115].
Overall, these different studies suggest various roles for
tenascin-C in controlling processes crucial to stem cell
homeostasis and mobilization in various physiological and
tumor contexts. It will therefore be of further interest to
study the contribution of tenascin-C in stem cells, pro-
genitors, and cancer stem cell contexts and in particular
determine through which signaling activities tenascin-C is
implicated. Such studies will with no doubt pave the way
towards novel translational opportunities for patients in
regenerative and cancer medicines.
Tenascin-C expression in cancers: prognostic value
and correlation to clinical outcome
As mentioned above, tenascin-C expression is tightly reg-
ulated during the adult lifespan and is mostly restricted to
physiological conditions requiring active remodeling of
tissue such as wound healing and inﬂammation [1, 47]. Its
increased expression has been reported in the stromal
compartment of cancers from various origins and was
recently reviewed [1]. Here we present recent data further
illustrating that tenascin-C expression represents a predic-
tive value for local recurrence and metastatic dissemination
of breast cancers, GBM, and other cancer types. Signiﬁcant
advances have also been made to characterize the spliced
isoforms of the molecule present in speciﬁc cancer tissues
[114], their histological localization and mechanistic sig-
nals controlling their expression [37], and role in cancer
cell invasion [114].
Tenascin-C in breast cancers
Tenascin-C was early described as a stromal marker
associated with malignant behavior of breast cancers [116].
Large spliced variants of the molecule containing exons 16
or 14/16 (coding for FNIII repeats A4 and AD2, respec-
tively) seemed correlated to invasion [117] and exon 15
(encoding FNIII repeat B) expressing tenascin-C was
detected at the invasive front of breast ductal carcinoma in
situ [118]. More recently, TNC-16 and TNC-14/16 were
shown to be highly expressed, and to upregulate the
expression of the matrix metalloproteinase 13 in different
invasive breast carcinoma cell lines, thereby stimulating
their invasive potential [119]. Expression of tenascin-C
isoforms in breast cancers can be elicited by various stimuli
including low pH and TGF-b. Moreover, in situ hybrid-
ization revealed that different splice variants of tenascin-C
can coexist in the same tumor tissue, suggesting that pre-
cise local microenvironmental cues determine the spatial
conﬁnement of speciﬁc isoforms that may functionally
differ [114]. The same authors correlated expression of
AD1 domain harboring tenascin-C with estrogen negative
grade 3 breast carcinomas in young women [120]. Spliced
isoforms of tenascin-C might therefore be associated with
speciﬁc pathological contexts and may determine clinical
outcome.
Transcriptomic analysis led to the incorporation of
tenascin-C among a list of genes that contributes to breast
cancer metastagenicity to the lung [121]. Tenascin-C was
conﬁrmed to be part of a gene signature relevant to lung
metastasis through tumor xenograft of MDA-MB-231 cells
derivatives presenting distinct invasive properties in nude
mice. Moreover, miRNA proﬁling revealed that tenascin-C
and Sox4 were down-regulated targets of miR335 and
correlated with aggressive behavior and propensity of
breast cancer cells to colonize the lung [122]. Interestingly,
tenascin-C was also reported to be a direct target of Sox4
transcriptional regulation in prostate cancer cell lines,
suggesting an ampliﬁcation loop of its expression that
could also be associated to invasive abilities of other cancer
models [123]. A tumorigenic function of tenascin-C was
also evoked in a three-dimensional acinar culture model of
non malignant MCF-10A cells externally delineated by a
basement membrane [124]. When cultured in the presence
of tenascin-C, MCF-10A acini deposited a loosely orga-
nized basement membrane and presented an elevated level
of c-Met (HGF/scatter factor receptor) expression inducing
luminal ﬁlling and cell proliferation, which is reminiscent
of early steps in breast cancer. This effect was reversed by
functional blocking of the proto-oncogene, and suggested a
new tumorigenesis supporting function of tenascin-C in
breast cancer. Moreover, tenascin-C expression in breast
cancer tissue could have consequences to anti-cancer
treatment responsiveness, as illustrated by a recent study
that correlated tenascin-C expression to shorter survival of
tamoxifen-treated patients with estrogen-positive breast
cancer [125].
Tenascin-C in brain tumors
GBM are among the most common malignant brain
tumors, and are characterized by genomic instability,
intense vascularization, and unpredictable clinical behav-
ior. Because of their adaptivity to anti-cancer drug
treatment, GBM present a poor prognosis and a limited
number of clinical targets have been referenced so far.
Tenascin-C is highly expressed in GBM and has been
associated with local invasion, shorter disease-free survival
[126], and worse overall survival prognosis (Fig. 2). A
study on a large set of gliomas revealed that strong peri-
vascular staining of tenascin-C is associated with tumor
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oma cell lines inhibited proliferation and migration,
suggesting that tenascin-C could constitute a reliable
marker and a potential therapeutic target [127]. Tenascin-C
expression was recently included in a list of nine genes that
had predictive value in GBM malignancy and was associ-
ated with mesenchymal differentiation of GBM cells and
angiogenesis [128]. An elevated expression of tenascin-C
was also detected in oligodendrocytomas, astrocytomas in
addition to GBM tissues as compared to healthy brain
samples [129].
A recent study showed that tenascin-C knock down in
the human LN229 GBM cell line had no signiﬁcant in vitro
effect on cell proliferation but abolished cell migration by
promoting focal adhesion disassembly signals [130]. Upon
orthotopic xenografting, control tumors presented frequent
cell clusters detached from the principal tumor mass that
were surrounded by tenascin-C. In contrast, tenascin-C
knocked down tumors had a decreased number of glioma
cell clusters inﬁltrating adjacent brain parenchyma.
Through MRI of patients with GBM, the authors correlated
the volume of peritumoral reactive parenchyma, which can
result either from focal brain edema or structural modiﬁ-
cation following GBM inﬁltration, to high tenascin-C
mRNA levels measured in surgical explants [130]. Tenas-
cin-C was also involved in the control of certain MMPs by
GBM cells. The presence of tenascin-C in three-dimen-
sional collagen gels increased the production of MMP-12
by GBM cell lines. Although the cell surface recep-
tor(s) involved remains to be determined, tenascin-C
induction of MMP-12 was PKC-d-dependent, and could
have clinical relevance. Indeed, GBM cell invasion was
stimulated by tenascin-C-induced MMP-12 and its
expression was detected in high-grade GBM [131, 132].
Some mechanistic insight for high tenascin-C expression in
gliomas was recently documented [133]. Tissue micro-
arrays revealed a high prevalence of tenascin-C co-
expression with RBPJk protein, a transcriptional cofactor
of Notch2, in GBM samples. Tenascin-C expression in
GBM cells was explained by RBPJk/Notch2 dependent
transactivation and ﬁnally, knocking down RBPJk signiﬁ-
cantly reduced tenascin-C expression and decreased GBM
cell motility.
Tenascin-C expression in other cancers
Tenascin-C was reported as an indicator of bad prognosis
in other tumor contexts such as head and neck cancers
[134, 135]. It was recently conﬁrmed through RT-PCR on
158 parafﬁn-embedded specimens that high expression of
tenascin-C, concomitant to angiopoietin-like 4, was
TNC low
n = 102
TNC high
n = 241
Fig. 2 High Tenascin-C expression correlates with poor outcome for
glioma patients. Publicly available gene expression proﬁling data
[190] were used to stratify glioma patients according to the level of
over-expression of TNC in these tumors (compared to normal brain
tissues) and to perform Kaplan–Meier analyses. Individuals with the
highest levels of TNC over-expression ([6-fold) have a highly
signiﬁcant worse prognosis (p\10
-9, logrank test)
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senting oral tongue squamous cell carcinoma [136].
Tenascin-C could also represent a promising biomarker in
giant cell tumors of bones since an elevated tenascin-C
level, assessed by microarray analysis and immunohisto-
chemistry, was shown to have predictive value for both
local recurrence and metastasis of these highly aggressive
cancers [137]. Interestingly, strong immunoﬂuorescent
staining of the FNIII A1 domain of tenascin-C has recently
been observed in a large set of non-Hodgkin and Hodgkin
lymphomas [138]. The same authors reported a strong
reactivity for this tenascin-C isoform in tumor-associated
vasculature of renal cell carcinomas and atypical carcinoid
of the lung [139].
Tenascin-C in tumor angiogenesis
Tumor angiogenesis is one of the hallmarks of cancer
[140]. In order to grow, a tumor needs to trigger angio-
genesis, an event that has been termed ‘‘the angiogenic
switch’’, which represents an imbalance from anti- to pro-
angiogenic factors driving the transition from a dormant
and poorly perfused to a proliferating and vascularized
tumor. The angiogenic switch can be triggered by hypoxia,
several stromal and tumor cells, and ECM compounds of
the reactive tumor microenvironment [141]. The tumor
neovasculature usually exhibits severe abnormalities: ves-
sels are tortuous and can be leaky due to poor endothelial
cell intercellular cohesion, partial pericyte coverage and a
disorganized basement membrane. These chaotic features
can be favorable for immune cell inﬁltration that may
promote reactivity of the tumor stroma and may provide
conducive gateways for motile tumor cells. A large number
of studies were thus devoted to design anti-angiogenic
strategies aiming at starving tumors and inducing their
subsequent shrinkage. Some of them have been clinically
approved, one of the most frequently applied being bev-
acizumab (or Avastin
, a VEGF-blocking humanized
antibody). However, anti-angiogenic treatments have
demonstrated partial efﬁcacy in certain cancers where
resistance and escape mechanisms can occur and were
sometimes shown to promote metastasis. In such cases,
angiogenesis-targeting cancer treatments have now been
revisited and redirected towards tumor vascular normali-
zation in order to optimize anti-cancer drug delivery [142].
ECM proteins, such as cellular ﬁbronectin (cFN) and ten-
ascin-C, have demonstrated promising potential in tumor
vascular targeting [143]. Hereafter are presented recent
data illustrating the crucial impact of tenascin-C on tumor
angiogenesis and some emerging concepts that could be
instrumental for the development of new clinical strategies
targeting the tumor vasculature.
Tenascin-C as speciﬁc marker of the tumor vasculature
Tenascin-C has previously been speciﬁcally observed at per-
ivascular location in GBM [127] and it was proposed that
different splicing isoforms could be deposited around tumor-
supplying blood vessels in speciﬁc patterned manner [1, 143,
144]. In gliomas, blood vessel localization of tenascin-C has
recently been conﬁrmed [145]. Due to clear codistribution
with desmin-expressing cells, it was also speculated that
pericytes could be a source of tenascin-C. Tenascin-C pres-
ence in the vascular bed is likely to inﬂuence maturation of
tumor vessels and could exert both scaffolding and remodel-
ing functions during early steps of tumor vessel formation.
Consistently, a strong immunoreactivity for tenascin-C has
been reported in renal cell carcinomas and lung cancers in
close vicinity to CD31-positive endothelial cells [139].
Remarkably, EDB (extradomain B)-containing cFN (cellular
or oncofetal ﬁbronectin) and tenascin-C exhibited a stratiﬁed
distributionpattern in tumor vessels,cFN beingmostlyfound
at the luminal and tenascin-C at the extraluminal site.
Two independent recent studies have been dedicated to
tumor vascular marker screening through proteomic
approaches [146, 147]. Both studies reported a positive
matchfortenascin-Cinvascularstructuresofdifferenttumor
models. The ﬁrst study was based on a syngenic heterotopic
model of colon carcinoma cell metastasis to the liver [146].
After in vivo biotinylation and puriﬁcation of proteins
accessible to blood perfusion, liver samples were analyzed
andcomparedtohealthyanimals.Tenascin-Clargeisoforms
(A1/A2/A4 or B domain-containing spliced variants) were
speciﬁcally found in metastasis-bearing liver samples. The
second study was based on laser capture microdissection of
vascular structures from invasive ductal breast carcinoma
tissue followed by mass spectrometry [147]. Here, tumor
vessel-enrichedsampleswerecomparedtotheadjacentnon-
malignant tissue to specify a protein signature of tumor
microvessels. This signature consisted of 86 overexpressed
proteins,includingtenascin-C.Theseapproachesrepresenta
signiﬁcantcontributiontoourunderstandingoftheproteome
and its rearrangements occurring in the tumor vasculature.
Finally,theystronglyreinforcethenotionthattenascin-Cisa
robust tumor vessel marker that could be used for cancer
imaging and clinical interventions.
Potential functions of tenascin-C in regulating
angiogenesis
Direct functions of tenascin-C in normal and tumor
vasculatures
Tenascin-C has been related for a long time to angiogenesis
in various physiological and pathological contexts,
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neovascularization in a murine corneal injury model
induced by cauterization [148]. This was explained by
suppression of VEGF and TGF-b1 expression by stromal
ﬁbroblasts and reduced macrophage inﬁltration at the
injury site. A high perivascular tenascin-C expression was
recently associated with cerebral arteriovenous malforma-
tions, a pathology characterized by direct connections
between arteries, draining veins and cerebral parenchyma
which are responsible for subarachnoid bleeding [149].
Tenascin-C null mice exhibited a weaker post-aortotomic
neointimal hyperplasia than their wild-type counterparts
[63], and deﬁcient revascularization of post-ischemic heart
resulting from reduced endothelial progenitor cell recruit-
ment [150]. The past literature on the role of tenascin-C in
angiogenesis and vasculogenesis has been reviewed else-
where [1], and therefore, here new literature will be
described in context of previous results. It has previously
been demonstrated that tenascin-C can regulate the
expression of proangiogenic factors relevant to cancer
outcome, including the prototypic angiogenic cytokine
VEGF-A [151]. In this study, A375 melanoma cells co-
cultivated with embryonic stem cells isolated from tenas-
cin-C null mice secreted a signiﬁcantly reduced amount of
VEGF-A as compared to the wild-type condition, sug-
gesting a tenascin-C dependent stromal-induced angiogenic
loop. When subcutaneously transplanted, tumors originated
from melanoma cells presented a net decrease of capillary
numbers in the absence of host tenascin-C. It is likely that
stromal and tumor cell-derived tenascin-C controls other
potent angiogenic signaling, for example, such as EDNR-A
and EDNR-B (endothelin receptors type A and B) and
PDGF-BB expression and signaling, notably in glioma
cells [1, 152, 153].
A direct function of tenascin-C in the control of vascular
instability of tumor vessels could rely on its well-refer-
enced action in ECM remodeling. A paradigm of a
combined action of two matrix molecules on tissue
remodeling has been described for tenascin-C and cFN
(reviewed in van Obberghen-Schilling et al. 2011). These
two ECM proteins are frequently codistributed in dynamic
vascular structures and growing evidence suggests that they
have overlapping patterns of expression around tumor
vessels [139]. We presume that these histological obser-
vations might not be fortuitous, especially during tumor
angiogenesis. Cryptic motifs of tenascin-C comprised in its
FNIII repeat domain were recently shown to interfere with
ﬁbronectin ﬁbrillogenesis, and its carboxy-terminal FBG
domain is able to potentiate its cellular uptake [27].
Fibronectin can exert a stabilizing function in capillary
morphogenesis maturation and functions as a signaling
platform in cell presentation of angiogenic cytokines [154,
155]. Considering the well-documented counter adhesive
actions of tenascin-C on ﬁbronectin substrata [1], it is
possible that speciﬁc tenascin-C domains are unmasked in
the perivascular bed of a tumor due to binding of tenascin-
C to ﬁbronectin or other ECM molecules. A large isoform
of tenascin-C was induced in ﬁbrosarcoma cells upon
knock down of S-adenosylmethionine decarboxylase and in
vivo, aberrantly organized tumor vessels were found sur-
rounding the xenografted tumor cells [156]. Hypoxic stress
is a hallmark of tumor stroma that can foster the angiogenic
switch of tumors by inducing a genetic reprogramming of
stromal and tumor cells leading to increased production of
proangiogenic factors [140]. One study had reported that
tenascin-C expression can be induced by hypoxic stress and
support branching morphogenesis of fetal lung explants
[157]. Interestingly, tenascin-C expression was recently
correlated with hypoxia and lymph node metastasis of
medullary thyroid carcinomas [158]. Wnt signaling repre-
sents a proangiogenic pathway that seems to be triggered
by tenascin-C. Wnt emerged as prominent morphogenic
signal controlling sprouting angiogenesis in a wide array of
physiopathological contexts [159, 160]. Tenascin-C was
shown to control the expression of the Wnt antagonist
DKK-1 in a GBM cell line [161]. More recently, a
decreased expression of a DKK-2 homologue was detected
in tenascin-C-deﬁcient MEFs comparing to the wild-type
level, suggesting high DKK2 expression in the presence of
tenascin-C [162]. As DKK-1 and DKK-2 were shown to
exert opposite effects on angiogenesis with DKK-1 inhib-
iting and DKK-2 stimulating angiogenesis, a potential
function of tenascin-C in the regulation of this balance in
tumor-associated endothelial cells would warrant an in-
depth assessment [99].
GBM certainly represent a model of choice to further
characterize the proangiogenic functions of tenascin-C.
GBM exhibit a strong plasticity, which could explain the
frequently observed resistance to traditional anti-cancer
drugs and anti-angiogenic treatment. In addition to
sprouting angiogenesis alternative vascularization mecha-
nisms that comprise vascular cooption, angioblast
vasculogenesis, intussusceptive microvascular growth, and
vasculogenic mimicry are found in GBM [163]. Under-
standing tenascin-C-associated angiogenesis in GBM could
therefore be instrumental in unraveling the many functions
of tenascin-C in tumor vessel plasticity, which could be
useful in the development of novel therapeutic opportuni-
ties [164, 165].
Tenascin-C-enriched matrix channels
In certain tumor models, stroma-incorporated tenascin-C
can be found in tube-shaped structures characterized by
ﬁbrillar patterns. Seminal observations of these ‘‘matrix
channels’’ were made in aggressive melanoma, which have
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node metastasis. Tenascin-C was distributed in a tubular
meshwork, together with ﬁbronectin and procollagen-I,
which wrapped around melanoma cell nests containing
erythrocytes [166]. The presence of red blood cells in
matrix channels suggested that these structures could form
a continuum between vascular and avascular areas of tumor
tissue. This consideration also intuitively led to the
assumption that tenascin-C-enriched matrix channels could
serve as the primary scaffold for tumor angiogenesis and
might serve in vascular cooption. A parallel could be
drawn to the concept of vasculogenic mimicry, which
initially referred to the ability of aggressive melanoma to
form vascular conduits through expression of endothelial
features by tumor cells [167].
Tenascin-C is physiologically abundant in reticular
ﬁbers of lymphoid organs [168–170]. These ECM-rich
conduits have been proposed to have crucial functions in
the education, maturation, and trafﬁc of immune cells [47].
A recent study has conﬁrmed the speciﬁc localization of
tenascin-C in the reticular ﬁbers of the lymph node cortex
and proposed that these conduits could constitute permis-
sive paths for lymphocyte migration [171]. A provocative,
but not less compelling hypothesis resulting from these
observations is a potential role of tenascin-C in regulating
cell trafﬁcking not only in the lymph node but also during
tissue repair and in cancer tissue by inﬂuencing the
recruitment of circulating cells from the blood stream. This
possibility is supported by the observation that recruitment
of endothelial progenitor cells into an area of revasculari-
zation after ischemia is impaired in tenascin-C null mice
[150].
Tenascin-C-enriched matrix channels could also be
relevant for tumor cell metastagenicity by providing
guiding cues promoting tumor cell escape. It is noteworthy
that the tenascin-C-containing matrix channels were qual-
iﬁed as an ‘‘invasion-associated ﬁbrillar network’’ [166].
Tumor cells and ﬁbroblast outgrowing from tumor tissues
by using a mesenchymal type of invasion have been
imaged through high-resolution time-lapse imaging of or-
ganotypic 3D cultures of tumor spheroids [172, 173].
Depending on the tumor, different modes of invasion were
observed. Pioneer invading cells can leave the tumor mass
in a single cell ECM remodeling invasion mode. Resulting
lytic paths were shown to be colonized by trailing squa-
mous cell carcinoma cells, which can individually or
collectively take advantage of these preformed ECM tubes
to disseminate [172]. It is likely that matrix channels are
reminiscent manifestations of past invasive cell move-
ments. Moreover, a potential ascendance and common
feature of matrix channels with vascular structures might
be instrumental in providing guiding cues for sprouting
angiogenesis, or other neovascularization modes.
Melanoma cells were reported to use the abluminal side of
tumor vessels when leaving primary tumors [174]. It is
tempting to speculate that tenascin-C-enriched matrix
channels could fuel similar tropisms in GBM and other
cancers.
Finally, matrix channels could constitute protective
niches for tumor and stromal cells. By providing speciﬁc
ﬁbrillar ECM micropatterns, tenascin-C-enriched tubular
structures are likely to conﬁne and select tumor and stromal
cell subpopulations and could therefore be relevant for
driving speciﬁc cellular functions and directing differenti-
ation status that could be advantageous for tumor stem cells
during treatment with anti-cancer drugs. Tenascin-C was
involved in the recruitment of bone-marrow-derived
endothelial progenitor cells at injury sites for revasculari-
zation [150]. This mode of control of neovessel formation
has not been investigated in the tumor context in depth.
Tenascin-C was recently detected in subpopulations of a
tumor that had demonstrated resistance to anti-cancer drug
treatment and has been involved in tumor-derived endo-
thelial cell selection [114, 115]. Tenascin-C would thus
possibly emerge as a targetable molecule in highly adaptive
cancers resistant to conventional treatments.
Immunomodulatory functions of tenascin-C in cancer
Several immunomodulatory functions were ascribed to
tenascin-C in various contexts, including early responses to
pathogens, injury, and chronic inﬂammation (reviewed in
[47]). Tenascin-C is involved in the regulation of both
innate and adaptive immune systems and was shown to
control the expression of various cytokines and the
recruitment of immune cells into inﬂammatory or injury
sites [48, 148]. Tenascin-C may also have immunomodu-
latory functions in the tumor context, although there is
limited data available. In support of this possibility, it was
found that in PyMT induced murine mammary cancer, the
number of inﬁltrating monocytes and macrophages was
increased in a tenascin-C null background [175]. Tenascin-
C ablation was also seen to provide protection against
chronic inﬂammation, such as in rheumatoid arthritis [48]
or in bronchial asthma in the mouse [176]. It has recently
been shown that tenascin-C produced by GBM cell lines
can inhibit transmigration of CD3
? T lymphocytes through
a monolayer of tumor cells in vitro [114]. This effect
seemed speciﬁc to GBM since it was not seen in mono-
layers of hepatocellular or breast carcinoma cell lines. It
was also described that T cells required a tenascin-C/ERK-
MAPK-dependent amoeboid-like morphological adapta-
tion to become polarized for transmigration. Interestingly,
CD3 ? T cell were found accumulated in blood vessels
surrounded by tenascin-C in glioma tissue. Assuming that
tenascin-C emerges as a vascular marker in certain tumors,
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in the stroma. Tenascin-C expression in tumor stroma
appears to also play a critical role in innate immunity
modulation. This concept is supported by the contribution
of tenascin-C to chronic inﬂammatory situations [47] and
by studies having described its impact on tumor inﬁltration
by monocytes and macrophages [175]. In some studies,
tenascin-C has demonstrated speciﬁcity in recruiting mac-
rophages versus other myeloid cells to the injury site [148].
It is noteworthy that chronic inﬂammation is another
hallmark of cancer [140], and myeloid lineage cells can
support neovascularization by releasing proangiogenic
cytokines in the tumor stroma [177].
In light of recent advances that illustrated tenascin-C
perivascular expression in tumor vessels, expression in
tumor nests connected to the blood circulation and its
inﬂuence on immune cell inﬁltration in tumors, an
improved understanding of the role of tenascin-C in tumor
homing of bone marrow-derived cells could open impor-
tant perspectives for designing novel anti-angiogenic
therapies.
Tenascin-C as a target for anti-cancer treatment: new
tools for imaging and clinical management of cancer
As stromal and tumor vascular markers, relevant for
numerous aggressive cancers, large isoforms of tenascin-C
have been envisaged as a powerful anti-cancer target for
many years. Without stating exhaustively past and present
results of these approaches, we propose a short review of
imaging and clinical strategies that have been designed and
will discuss recent data that could give future perspectives
for anti-cancer drug design based on our knowledge about
tenascin-C.
Tenascin-C-targeting strategies include silencing
approaches, in situ imaging of its expression through
immunoﬂuorescent and radiolabeled probes suitable for
immuno-PET and MRI contrasting, and delivery of cyto-
kines or radionuclides using tenascin-C-speciﬁc antibody
or aptamers (summarized in Table 2). An antibody speciﬁc
for FNIIIC domain of tenascin-C, in SIP format (phage-
developed small immunoprotein) had proven to be useful
for selective delivery of radioiodine and interleukine-2 to
U87 glioma cell-based tumor grafts in mice [178]. An
effective regression of U87 gliomas was also observed with
anti-FNIIIA1 and anti-FNIIID SIP antibodies (F16 and
P12, respectively) [144]. A clinical study based on
131I-(81C6)-coupled anti-tenascin-C administration, adju-
vant to temozolomide (the standard treatment for GBM), in
malignant gliomas, proved good tolerance in GBM patients
and was pursued in a randomized trial [179]. This antibody
was also tested as a vector for a-emitting particles in
malignant brain tumors and demonstrated no neurotoxicity,
speciﬁc local delivery, and, despite a too small number of
patients, an encouraging median survival time for GBM
patients, as compared to other treatment [180]. Neuradiab

(Bradmer Pharmaceuticals, Inc.), the commercial name of
the 81C6 anti-tenascin-C antibody is currently in phase II
trials in combination with Avastin
 in patients with GBM
but results have not yet been published. In another study
with 46 GBM patients, double-strand RNA directed against
tenascin-C was directly injected into the surgical cavity
after tumor resection. This approach showed improved
quality of life and signiﬁcant efﬁcacy, as compared to
standard brachytherapy, by increasing overall survival time
of 13.2 and 13.9 weeks for grade III gliomas and GBM,
respectively [181].
Tissue staining with the F16 SIP antibody revealed high
tenascin-C expression in non-small cell lung carcinomas,
human Hodgkin or non-Hodgkin lymphomas, renal cell
carcinomas, or head and neck cancers, with tumor-speciﬁc
stromal and vascular patterns [138, 139, 182–184]. The
F16 antibody coupled to interleukin-2 (IL-2) was recently
shown to signiﬁcantly improve therapeutic beneﬁt obtained
with paclitaxel or doxorubicine treatments in a mouse
xenograft model of human breast cancer [185]. Breast
cancer patients are currently recruited in phase I/II trials for
administration of F16-Il-2 combined with paclitaxel or
doxorubicine, or as single treatment with
131I-F16. It is
becoming clear that tumor-, patient-, stage-speciﬁc infor-
mation on expression patterns of tenascin-C isoforms could
be helpful for therapy decisions.
An additional emerging alternative to these antibody-
based tenascin-C-targeting strategies, which can present
the major drawback of being mono-speciﬁc, could consist
in the design of multimodal nanoparticles. In such
approaches, particles functionalized with aptamers present
several advantages. Adjustable and applicable for multiple
tumor marker speciﬁcity, they could limit off-target effects
in normal tissue or towards stromal cells that exert anti-
cancer functions, and are suitable for ﬂuorescence and
nuclear imaging as well. One recent study presented a
novel multimodal nanoparticle which has been called
SMART (for simultaneous multiple aptamers and RGD
targeting) [186]. It combines triple afﬁnity for nucleolin,
RGD-containing integrins and tenascin-C and demon-
strated higher afﬁnity for cell surface of different cancer
cells than single aptamers. Although not yet tested in
preclinical studies, this kind of strategy presents a prom-
ising opportunity and could be developed into clinical
applications in the near future. Altogether, these recent
advances should undoubtedly improve the accuracy of anti-
cancer drug delivery, could present great potential for
counteracting anti-angiogenic resistance, and have already
opened new therapeutic avenues in clinical targeting of
cancer.
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Imaging tenascin-C in cardiac pathology
Given the signiﬁcant correlation between high local and
systemic tenascin-C expression and poor cardiac function,
much interest has been stimulated in imaging tenascin-C
expression during heart disease. After intravenous admin-
istration of an anti-tenascin-C antibody labeled with
111Indium into rats with experimental autoimmune myo-
carditis, Sato and collaborators were able to image the
distribution of the antibody using a biotracer. The antibody
was rapidly cleared from the bloodstream but uptake was
signiﬁcantly enhanced in the myocardium of rats with
myocarditis by 6 h and maintained up to 48 h. High
radioactivity was observed speciﬁcally in the inﬂammatory
lesions and single-photon emission CT imaging demon-
strated the focal myocardial uptake of 111In anti-TNC Fab’
occurred during disease [14]. More recently, Taki and
collaborators used an I
125-labeled tenascin-C antibody to
demonstrate the feasibility of spatiotemporal proﬁling of
tenascin-C expression after myocardial ischemia and
reperfusion. Autoradiography of murine heart tissue 24 h
after 20 min of ischemia and reperfusion revealed signiﬁ-
cant tenascin-C expression, predominantly in the
midmyocardial to endomyocardial layers. Expression
peaked at 3 days, and was followed by a marked reduction
of tenascin-C expression at 7 days. However, when the
ischemia was prolonged to 30 min, the time course of the
tenascin-C expression differed considerably; it peaked at 1
and 3 days after reperfusion, and a reduced but still sig-
niﬁcant expression persisted over 7–14 days, followed by
an obvious decline in tenascin-C expression at 28 days
[12]. Finally, a tenascin-C Fab has also been used to detect
LV remodeling during cardiac repair after MI in rats, an
important prognosticator of patient outcome. The locali-
zation of the
111In-labeled antibody after intravenous
injection by dual-isotope single-photon emission computed
tomography was revealed to be signiﬁcantly higher in the
heart tissues. Autoradiography of excised tissue conﬁrmed
this ﬁnding and additionally demonstrated a speciﬁc dis-
tribution to infarcted areas compared to non-infarcted,
validating the use of this technique in vivo and highlighting
Table 2 Tenascin-C targeting in anti-cancer therapies
Cancer type Strategy Stage Result/outcome Reference
Mouse orthotopic
xenograft—U87
human GBM—A375
human melanoma
F16 (anti-domain A1) and P12
(anti-domain C) anti-tenascin-C
antibodies administration
Preclinic Tumor-speciﬁc targeting of F16 antibody [144]
Mouse subcutaneous
and rat orthotopic
xenografts, U87
human GBM
G11 (anti-domain C) anti-tenascin-
C SIP antibody coupled to IL-2
or radioiodinated
Preclinic Selective tumor uptake and
immunoreactivity
[178]
Mouse orthotopic
xenografts—U87
human GBM
F16 antibody coupled to IL-2—
combination with temozolomide
Preclinic Tumor growth inhibition—prolonged
survival
[200]
Mouse xenografts—
MDA-MB-231
human breast cancer
cells
F16 antibody coupled to IL-2—
combination with doxorubicine
or paclitaxel
Preclinic—currently
recruiting patients in
phase I/II breast
cancer
Increased beneﬁts (reduced tumor growth/
prolonged survival) compared to
uncoupled IL-2—improved beneﬁts
with chemotherapy
[185]
Human malignant
glioma patients
131I-81C6 anti-tenascin-C
antibody—injection in surgical
resection cavity -radiotherapy—
temozolomide
Clinic-tested in phase III
trials
(unpublished)other
phase I/II ongoing
Good tolerance to treatment [179]
Human malignant brain
tumors
Alpha-particle emitting astatine-
221-coupled 81C6 anti-tenascin-
C—injection in surgical cavity
Clinic currently in phase
I/II patients with
primary or metastatic
brain tumors
No detectable neurotoxicity [180]
Human brain tumors-
GBM
siRNA against tenascin-C—
application in post surgical
resection cavity
Clinic Improved survival as compared to
brachytherapy—improved quality of
life
[181]
Various human cancer
cell lines
Multimodal nanoparticles with
tenascin-C aptamers
(cospeciﬁcity for nucleolin and
RGD-dependent integrins)
Not tested for clinical
applications
Increased cell surface speciﬁcity as
compared to single aptamers
[201]
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[187]. Together, these data demonstrate that both immun-
oscintigraphic imaging and measuring serum tenascin-C
may provide new non-invasive approaches for the diag-
nosis of myocardial disease activity.
Imaging atherosclerotic plaques
Methods for imaging atherosclerotic plaques exploiting
tenascin-C expression are also emerging. The ﬁrst clue that
this may be useful came from studies examining why
gadoﬂuorine M, used during MRI to improve imaging of
plaques, confers enhanced speciﬁc detection of plaque
tissue versus the normal vessel wall. It was found that
gadoﬂuorine M speciﬁcally accumulates in plaques via
several interactions; it can bind to serum albumin, which
complex is thought to penetrate into the plaque where it
then co-localizes to areas of ﬁbrous ECM accumulation.
In vitro analysis by microdialysis demonstrated that gad-
oﬂuorine M binds to puriﬁed ECM components of the
plaque, including collagens and tenascin-C, with a kD of
*2 lM[ 188]. Subsequently, the antibody G11 which
speciﬁcally recognizes the alternatively spliced C domain
of tenascin-C, an isoform that is enriched in atherosclerotic
plaques, was used to visualize late and inﬂamed or ruptures
plaques in ApoE mice on a high-cholesterol diet. Consis-
tent with other reports that link high tenascin-C expression
to late-stage plaques, I
125-labeled G11 localized speciﬁ-
cally to the plaque lesion by 24 h. Upon ex vivo analysis it
was found to coincide with fat-rich areas and macrophage
inﬁltration. Antibodies were cleared from circulation by
24 h, creating a favorable blood:tissue ratio that highlights
the potential of this approach in imaging [65]. Finally,
antibody F16, which speciﬁcally recognizes the A1 domain
of tenascin-C, stained human carotid plaque tissue, but not
normal ileac arteries, localizing to regions rich in macro-
phages, proliferating cells, while much weaker staining
was observed in quiescent plaques [189]. These studies
highlight potential ways to image active remodeling during
plaque progression that could become useful tools in
patient diagnosis and disease management. Compared to
other available methods including ultrasound, computed
tomography, magnetic resonance imaging, and angiogra-
phy, this method may offer additional molecular insight
into plaque status.
Conclusions and future perspectives
Although tenascin-C is a rather ‘‘old’’ molecule, discovered
more than 30 years ago, it still reveals surprises to us,
evidenced by recent publications. Due to the modular
organization, post-translational modiﬁcation, and cleavage
pattern, there is not only one kind of tenascin-C molecule
in a given tissue, but these different tenascin-C entities
sometimes present simultaneously in the same microenvi-
ronment, greatly increasing the complexity of possible
interactions. Tenascin-C is a key molecule in tissue
remodeling and its deregulated high expression is causally
linked to many diseases, including heart failure, thrombo-
sis, atherosclerosis, and cancer. Mechanistically, tenascin-
C can have an impact on the microenvironment through
direct interactions with cells and growth factors as well as
with other ECM molecules, thus regulating tissue resilience
and cell responses such as cell survival, migration, prolif-
eration, stemness, and transdifferentiation. Due to
technological advances in the development of tenascin-C
targeting strategies, we are now facing a future where the
application of our basic knowledge about tenascin-C can
translate into the cure or amelioration of diseases.
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